Drug Profile
MK 7162
Alternative Names: MK-7162Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Canada (PO, Tablet)
- 28 Jan 2021 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Israel (PO, Tablet)
- 28 Jan 2021 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in South Korea (PO, Tablet)